Xigduo XR (linagliptin + metformin)
Dosage strength: 10 mg linagliptin / 1 000 mg metformin (often written 10 mg/1 000 mg).
---
1. What is it used for?
- Type 2 diabetes mellitus: It’s a combination tablet that helps lower blood sugar (HbA1c) when diet, exercise, and other oral agents aren’t enough.
- It can be used as:
- Monotherapy (if other meds are not suitable).
- Adjunctive therapy with another antidiabetic drug (e.g., insulin, sulfonylureas).
2. How does it work?
| Component | Mechanism | Key Benefit |
|-----------|-----------|-------------|
| Linagliptin | DPP‑4 inhibitor – blocks the enzyme that destroys GLP‑1, boosting GLP‑1 levels. | Lowers post‑prandial glucose, minimal hypoglycemia risk. |
| Metformin | Decreases hepatic glucose production, improves insulin sensitivity, and delays intestinal glucose absorption. | Reduces fasting glucose, modest weight neutral/positive effect. |
The combination is taken once daily with the same meal (any meal) to improve adherence.
3. Typical dosing
| Situation | Dose | Notes |
|-----------|------|-------|
| Start therapy | 10 mg/1 000 mg once daily | Take with a meal. |
| Adjust if needed | Increase to 20 mg/1 500 mg once daily | Only if HbA1c target not met and tolerated. |
| Renal impairment | Linagliptin is safe in CKD; metformin limited when eGFR < 30 mL/min/1.73 m² (avoid). | Adjust or avoid according to eGFR. |
Do not split tablets; take as prescribed.
4. Common side effects
| Symptom | Likelihood | Typical management |
|---------|------------|---------------------|
| Nausea, diarrhea, stomach upset | Mild–moderate | Take with food; consider a lower dose if severe. |
| Headache | Mild | Usually resolves with time. |
| Hypoglycemia | Rare (unless combined with other hypoglycemic agents) | Monitor blood glucose; adjust co‑meds if needed. |
| Weight gain (metformin) or neutral (linagliptin) | Mild | Encourage exercise & diet. |
| Allergic reactions (rash, itching) | Rare | Seek medical attention if severe. |
5. Serious warnings
| Issue | Why it matters | What to watch for |
|-------|----------------|-------------------|
| Lactic acidosis (very rare) | Metformin accumulates in renal or hepatic failure. | Symptoms: malaise, weakness, muscle pain, rapid breathing. |
| Renal dysfunction | Metformin contraindicated if eGFR < 30 mL/min/1.73 m². | Check creatinine before starting and periodically. |
| Allergic reactions | Can range from mild rash to severe anaphylaxis. | Seek immediate help if swelling, difficulty breathing. |
| Pancreatitis (very rare) | DPP‑4 inhibitors linked in case reports. | Severe abdominal pain that doesn’t improve. |
6. Drug interactions
- Insulin or sulfonylureas: ↑ hypoglycemia risk.
- Digoxin: Linagliptin may increase digoxin levels; monitor.
- Cimetidine or proton‑pump inhibitors: Metformin absorption can be affected.
- Antacids: Avoid taking with metformin for 1–2 h.
Always tell your healthcare provider about all medications, supplements, and herbs.
7. Storage
- Store at room temperature (≤ 25 °C / 77 °F), away from moisture and light.
- Keep out of reach of children and pets.
- Do not use past the expiration date.
8. What to do if you miss a dose?
- If you miss a dose by ≤ 12 h, take it as soon as you remember.
- If > 12 h has passed, skip the missed dose and resume the regular schedule. Do not double‑dose.
9. When to call your doctor
- Severe or persistent nausea, vomiting, or diarrhea.
- Signs of kidney problems (decreased urine output, swelling, confusion).
- Symptoms of hypoglycemia or unexplained fatigue.
- Any rash, itching, swelling, or breathing difficulty.
---
Bottom line
Xigduo XR is a once‑daily combo pill that blends the strengths of linagliptin and metformin to lower blood sugar in type 2 diabetes. It’s generally well tolerated, but careful attention to renal function and monitoring for hypoglycemia (especially if you’re on other glucose‑lowering drugs) is key.
If you have any doubts about how it fits into your treatment plan, talk to your pharmacist or prescribing clinician. They can help tailor the dose, adjust for kidney function, and address any drug‑drug concerns.